Crossject Société Anonyme (EPA:ALCJ) On The Verge Of Breaking Even

We feel now is a pretty good time to analyse Crossject Société Anonyme's (EPA:ALCJ) business as it appears the company may be on the cusp of a considerable accomplishment. Crossject Société Anonyme develops needle-free injection systems in France. The €91m market-cap company announced a latest loss of €10m on 31 December 2025 for its most recent financial year result. As path to profitability is the topic on Crossject Société Anonyme's investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Crossject Société Anonyme is bordering on breakeven, according to the 2 French Medical Equipment analysts. They anticipate the company to incur a final loss in 2025, before generating positive profits of €28m in 2026. The company is therefore projected to breakeven around a year from now or less! At what rate will the company have to grow in order to realise the consensus estimates forecasting breakeven in under 12 months? Using a line of best fit, we calculated an average annual growth rate of 63%, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

We're not going to go through company-specific developments for Crossject Société Anonyme given that this is a high-level summary, though, take into account that typically a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

See our latest analysis for Crossject Société Anonyme

One thing we would like to bring into light with Crossject Société Anonyme is it currently has negative equity on its balance sheet. Accounting methods used to deal with losses accumulated over time can cause this to occur. This is because liabilities are carried forward into the future until it cancels. These losses tend to occur only on paper, however, in other cases it can be forewarning.

Next Steps:

There are too many aspects of Crossject Société Anonyme to cover in one brief article, but the key fundamentals for the company can all be found in one place – Crossject Société Anonyme's company page on Simply Wall St. We've also put together a list of relevant factors you should further examine:

1. Valuation: What is Crossject Société Anonyme worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Crossject Société Anonyme is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Crossject Société Anonyme’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.